# Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

> **NCT01527500** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 158 (actual)

## Conditions studied

- Geographic Atrophy
- Age-related Macular Degeneration

## Interventions

- **DRUG:** LFG316
- **DRUG:** Sham
- **DRUG:** LFG316 Lower dose

## Key facts

- **NCT ID:** NCT01527500
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-25
- **Primary completion:** 2015-06-24
- **Final completion:** 2015-06-24
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527500, "Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT01527500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*